Innovative Cooperation Unit of "Brain Science and Multi-Omics Research" of the Chinese Stroke AssociationAward Ceremony

METiS TechBio Awarded Plaque as an Innovative Cooperation Unit by the Chinese Stroke Association for "Brain Science and Multi-Omics Research"

During the conference, Dr. Sun Kaiqi, Strategic Director of METiS TechBio, delivered a keynote speech titled "AI-Driven Development of Drug Delivery Systems."As one of the world's leading drug delivery platforms, METiS TechBio, in the absence of open-source datasets and delivery-related algorithms, started from scratch to innovatively develop groundbreaking artificial intelligence and computational simulation algorithms for the generation and design of ionizable lipids as well as the design and simulation of LNP nanomaterials. By integrating world-class high-throughput experimental techniques and animal validation platforms, METiS TechBio has established a unique data and algorithmic barrier.

Based on the AI drug delivery platform, METiS TechBio has combined the rapidly developing large models and generative AI technology to establish the world's first METiSLipidLM lipid language model and PhatGPT lipid generation model, successfully creating a million-level lipid library and breaking through international patent barriers. Meanwhile, METiS TechBio utilizes innovative molecular simulation technology to simulate various microscopic processes of LNPs in vivo and in vitro. Relying on a world-class experimental validation platform, it has promoted the development of multi-organ targeted nanomaterials and successfully realized the application of AI + nanomaterials.

This award not only recognizes METiS TechBio's innovative capabilities in the fields of multi-omics and drug delivery but also highlights the company's significant role in promoting biomedicine technological innovation and the transformation of scientific achievements.In the future, METiS TechBio will continue to uphold the development concept of innovation-driven, utilizingAdvanced technology platform dedicated to drug development for unmet clinical needs, including central nervous system diseases such as stroke, as well as cancer and immunology, striving for greater breakthroughs and achievements in the biopharmaceutical field.